FibroGen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 486
- Market Cap
- $38.6M
- Website
- http://www.fibrogen.com
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-08-06
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 50
- Registration Number
- NCT01181245
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸Oregon Health Sciences University (OHSU), Portland, Oregon, United States
Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 161
- Registration Number
- NCT01147666
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 46
- Registration Number
- NCT00913393
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 2
- Registration Number
- NCT00782561
Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 117
- Registration Number
- NCT00761657
Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 38
- Registration Number
- NCT00754143
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
Phase 2
Completed
- Conditions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 145
- Registration Number
- NCT00456053
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
🇺🇸3 Research Sites, Los Angeles, California, United States
Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-01-27
- Last Posted Date
- 2007-12-12
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 20
- Registration Number
- NCT00102297
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Diabetes & Glandular Disease, San Antonio, Texas, United States
Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2003-12-22
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- FibroGen
- Target Recruit Count
- 21
- Registration Number
- NCT00074698
- Locations
- 🇺🇸
University of Michigan Health Sciences, Ann Arbor, Michigan, United States
🇺🇸Southwestern Medical School, Dallas, Texas, United States
🇺🇸National Jewish Medical and Research Center, Denver, Colorado, United States
© Copyright 2024. All Rights Reserved by MedPath